NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $92.65 +0.67 (+0.73%) (As of 05:41 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$91.02▼$92.8550-Day Range$89.81▼$104.1852-Week Range$81.14▼$105.47Volume5.60 million shsAverage Volume9.41 million shsMarket Capitalization$7.06 billionAssets Under Management$6.63 billionDividend Yield0.02%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.55%0.51%0.52%Other Expenses0.00%0.30%0.49%0.57%0.53%Total Expense0.35%0.70%0.71%0.73%0.71%Fee Waiver0.00%-0.45%-0.51%-0.67%-0.56%Net Expense0.35%0.61%0.61%0.58%0.59% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesSPDR S&P Biotech ETF declares quarterly distribution of $0.0027December 23 at 6:35 PM | msn.comLitecoin Price Forecast: Whales invest $950M in 73-day buying spree amid LTC ETF approval rumoursNovember 28, 2024 | fxstreet.comHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!December 26, 2024 | Darwin (Ad)Biotech ETF (XBI) ended a diagonal: Looking for buying dipsNovember 27, 2024 | fxstreet.comBiotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)November 19, 2024 | seekingalpha.comSPDR Series Trust SPDR S&P Biotech ETF (ARCA:XBI), Short Interest ReportNovember 19, 2024 | benzinga.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $89.29 at the start of the year. Since then, XBI stock has increased by 3.8% and is now trading at $92.65. View the best growth stocks for 2024 here. Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's top institutional shareholders include JPMorgan Chase & Co. (16.11%), Healthcare of Ontario Pension Plan Trust Fund (12.11%), Jane Street Group LLC and Parallax Volatility Advisers L.P.. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings171 Fund Statistics Assets Under Management$6.63 billion Average Daily Volume$8.51 million Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume7,745 Put Options3,077 Call Options4,668 Short Interest56,330,000 shs Miscellaneous Outstanding Shares76,220,000Beta1.11 Creation Unit50,000 Creation Fee$250.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Top 10 XBI HoldingsNeurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.51%AbbVie (NYSE:ABBV)Holding Weight: 2.40%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.37%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 2.36%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.36%Natera (NASDAQ:NTRA)Holding Weight: 2.28%Amgen (NASDAQ:AMGN)Holding Weight: 2.27%Incyte (NASDAQ:INCY)Holding Weight: 2.26%Sarepta Therapeutics (NASDAQ:SRPT)Holding Weight: 2.26%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.24%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.